Assess whether related-party sales should be backed out of valuation (f2c303)

SITUATION Related-party sales should be sits with customer-contract risk reviewer because a TSA that expires before replacement systems exist hit a strategic buyer looking at a carve-out from a conglomerate. Evidence is regulatory-approval critical-path calendar; write the M&A Due Diligence Separation and Integration option that extract can carry.

DECISION Customer-contract risk reviewer in a strategic buyer looking at a carve-out from a conglomerate must choose Proceed / Reprice / Walk / Hold using regulatory-approval critical-path calendar after a TSA that expires before replacement systems exist.

HYPOTHESES TO TEST 1. Customer-contract risk reviewer can defend Proceed from regulatory-approval critical-path calendar after a TSA that expires before replacement systems exist in a M&A Due Diligence challenge. 2. Customer-contract risk reviewer cannot defend Proceed from regulatory-approval critical-path calendar; Reprice is what the extract actually supports after a TSA that expires before replacement systems exist. 3. A TSA that expires before replacement systems exist never reached the population in regulatory-approval critical-path calendar — reopen intake, do not close related-party sales should be. 4. Two facts in regulatory-approval critical-path calendar after a TSA that expires before replacement systems exist conflict for customer-contract risk reviewer; hold this Separation and Integration file.

ANALYSIS REQUIRED 1. Test whether a TSA that expires before replacement systems exist is a diligence gap, a price chip, or a walk-away. 2. Separate a one-off add-back from a recurring earnings issue in regulatory-approval critical-path calendar. 3. Map reps, earnout mechanics, and integration risk a strategic buyer looking at a carve-out from a conglomerate would inherit. 4. For this M&A Due Diligence Separation and Integration file, read regulatory-approval critical-path calendar against a TSA that expires before replacement systems exist and write the one fact that would move related-party sales should be for customer-contract risk reviewer.

RECOMMENDATION Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / Separation and Integration packet (regulatory-approval critical-path calendar after a TSA that expires before replacement systems exist). The follow-on Separation and Integration action is what customer-contract risk reviewer does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line M&A Due Diligence option on related-party sales should be, then the evidence in regulatory-approval critical-path calendar, then the action for customer-contract risk reviewer - Hypothesis scorecard against regulatory-approval critical-path calendar: supported / rejected / untestable - Regulatory or exam hook Separation and Integration would cite - Separation and Integration finding in regulatory-approval critical-path calendar that a second reviewer can re-perform